• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Orthofix Medical Inc. (Amendment)

    2/9/24 11:02:19 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email
    SC 13G/A 1 ofix13gdec3123.txt 13G AMENDMENT CLOSE OUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Name of Issuer: Orthofix Medical Inc (OFIX) Title of Class of Securities: Common Stock CUSIP Number: 68752M108 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications: Paul Lythberg 540 W. Madison Street, Suite 1900 Chicago, IL 60661-2551 312-474-4122 Date of Event which Requires Filing of this Statement: December 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X]Rule 13d-1(b) [ ]Rule 13d-1(c) [ ]Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 68752M108 Page 2 of 5 Pages 1. NAMES OF REPORTING PERSONS SEGALL BRYANT & HAMILL, LLC 47-1788385 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ___ (b) ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER: 31,545 6. SHARED VOTING POWER: ___________ 7. SOLE DISPOSITIVE POWER: 44,484 8. SHARED DISPOSITIVE POWER: ___________ 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 44,484 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.1% 12. TYPE OF REPORTING PERSON IA CUSIP No. 68752M108 Page 3 of 5 Pages Item 1. (a) Name of Issuer Orthofix Medical Inc. (b) Address of Issuer s Principal Executive Offices 3451 Plano Parkway Leisville, TX 75056 Item 2. (a) Name of Person Filing Segall Bryant & Hamill, LLC (b) Address of the Principal Office or, if none, residence 540 W. Madison Street, Suite 1900, Chicago, IL 60661-2551 (c) Citizenship Delaware (d) Title of Class of Securities Common (e) CUSIP Number: 68752M108 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ X ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(J). CUSIP No. 68752M108 Page 4 of 5 Pages Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned:44,484 (b) Percent of class: 0.1% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 31,545. (ii) Shared power to vote or to direct the vote: ________. (iii) Sole power to dispose or to direct the disposition of: 44,844. (iv) Shared power to dispose or to direct the disposition of: ________. Instruction. For computations regarding securities which represent a right to acquire an underlying security see 240.13d-3(d)(1). Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ]. Instruction. Dissolution of a group requires a response to this item. Item 6. Ownership of More than Five Percent on Behalf of Another Person. NOT APPLICABLE Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. NOT APPLICABLE Item 8. Identification and Classification of Members of the Group. NOT APPLICABLE Item 9. Notice of Dissolution of Group. NOT APPLICABLE CUSIP No. 68752M108 Page 5 of 5 Pages Item 10. Certification. (a) The following certification shall be included if the statement is filed pursuant to 240.13d-1(b) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: 02/09/2024 Signature /s/ Paul Lythberg Name/Title : Paul Lythberg, Chief Compliance Officer/Chief Operating Officer
    Get the next $OFIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    7/19/2023$27.00Buy
    BTIG Research
    3/4/2022$41.00 → $45.00Hold → Buy
    Stifel
    More analyst ratings

    $OFIX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Orthofix Medical Inc.

      10-Q - Orthofix Medical Inc. (0000884624) (Filer)

      5/6/25 7:05:26 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Orthofix Medical Inc. (0000884624) (Filer)

      5/6/25 7:03:52 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Orthofix Medical Inc.

      DEFA14A - Orthofix Medical Inc. (0000884624) (Filer)

      4/30/25 4:15:12 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Orthofix Announces Appointment of Vickie Capps to Board of Directors

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa

      3/12/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b

      8/15/24 5:52:00 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Names Stephanie Walsh Chief Human Resources Officer

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H

      7/16/24 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

      SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

      11/14/24 5:20:27 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Orthofix Medical Inc.

      SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

      11/13/24 5:03:21 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

      SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

      4/22/24 5:00:33 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OFIX
    Financials

    Live finance-specific insights

    See more

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Canaccord Genuity initiated coverage on Orthofix with a new price target

      Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

      1/22/25 7:47:50 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by Stifel with a new price target

      Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously

      11/8/24 8:23:19 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by ROTH MKM with a new price target

      ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously

      5/8/24 6:31:28 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • New insider Mcpherron Aviva claimed ownership of 50,050 shares (SEC Form 3)

      3 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/9/25 4:24:43 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:38:02 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • New insider Engine Capital Management, Lp claimed ownership of 4,151,671 shares (SEC Form 3)

      3 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:34:36 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:38:02 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • President & CEO Calafiore Massimo bought $172,801 worth of shares (9,914 units at $17.43), increasing direct ownership by 5% to 222,404 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      3/6/25 4:27:08 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix to Report First Quarter 2025 Financial Results

      Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O

      4/15/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance

      Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account

      2/25/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance
    • Orthofix to Report First Quarter 2025 Financial Results

      Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O

      4/15/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care